AUTHOR=Franco Molina Moisés Armides , Reding Hernández David , García Coronado Paola Leonor , Kawas Jorge R. , Zárate Triviño Diana G. , Hernández Martínez Sara Paola , Castro Valenzuela Beatriz Elena , Rodríguez Padilla Cristina 

TITLE=Antitumor efficacy of silver nanoparticles reduced with β-D-glucose as neoadjuvant therapy to prevent tumor relapse in a mouse model of breast cancer

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 14 - 2023

YEAR=2024

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1332439

DOI=10.3389/fphar.2023.1332439

ISSN=1663-9812

ABSTRACT=Neoadjuvant therapy constitutes a valuable modality for diminishing tumor volume prior to surgical resection. Nonetheless, its application encounters limitations in the context of recurrent tumors, which manifest resistance to conventional treatments. Silver nanoparticles (AgNPs) have emerged as a promising alternative for cancer treatment owing to their cytotoxic effects. This study systematically assessed the cytotoxic impact of beta-D-glucose-reduced AgNPs (AgNPs-G) both in vitro and as a neoadjuvant intervention against breast cancer cells within an in vivo model. These findings demonstrate that AgNPs-G diminishes the cell viability of the 4T1 cell line in a dose-dependent manner. However, in an ex vivo assay against a solid tumor, a higher dosage is required to achieve a commensurate effect observed in the in vitro assay. In an in vivo model examining the biodistribution of AgNPs-G in different organs and tumors, a heightened concentration of silver was detected in tumoral tissue. Moreover AgNPs-G reduced Ki67 and collagen expression, and no difference in the percentage of apoptotic cells in metastatic foci in lungs were found compared with the control. Consequently, intratumoral administration emerged as the optimal route for AgNPs-G delivery, mitigating potential adverse effects in other organs stemming from silver accumulation.